AstraZeneca breast cancer trial setback

AstraZeneca (AZN) announced on 11 September 2026 that the Phase III SERENA-4 trial evaluating Etcamah, also known as camizestrant, in combination with the CDK4/6 inhibitor palbociclib did not meet its primary endpoint of progression-free survival. The study was designed to test the regimen as an upfront first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer.

The company reported that in the patient population evaluated, the Etcamah plus palbociclib arm delivered only a numerical improvement in progression-free survival. This level of benefit was not sufficient to satisfy the predefined primary endpoint of the trial.

The numerical improvement noted in SERENA-4 indicates that patients receiving the Etcamah and palbociclib combination experienced some delay in disease progression compared with the comparator arm, but not to a statistically significant degree required for success. As a result, the trial is considered a failure on its main efficacy measure, limiting the immediate prospects of this particular treatment combination in the first-line advanced setting.

The result represents a key outcome for Etcamah’s development in ER-positive, HER2-negative advanced breast cancer when used alongside palbociclib. The company did not provide further quantitative details on the progression-free survival data in the initial communication.

AstraZeneca (AZN) stated that the safety profile observed in SERENA-4 was consistent with the known safety profiles of each individual medicine in the combination. No new safety concerns were identified in the trial based on the information disclosed so far.

The company said it intends to share the full SERENA-4 data in due course. Further details on efficacy across subgroups, secondary endpoints, and additional safety analyses are expected when the complete dataset is presented.

The failure of SERENA-4’s primary endpoint is a setback for the strategy of combining Etcamah with palbociclib as a first-line option in ER-positive, HER2-negative advanced breast cancer. The outcome narrows the evidence base for this specific regimen, even though some numerical benefit in progression-free survival was observed.

With full results still pending, the disclosed findings primarily affect expectations for this particular Phase III trial rather than providing a comprehensive view of Etcamah’s broader clinical program. AstraZeneca (AZN) has signaled that more detailed data will clarify the performance of the regimen once released.